Journal de bioanalyse et de biomédecine

The rapid and accurate detection of infectious diseases is crucial for timely diagnosis and effective management. Point-Of-Care Testing (POCT) offers a promising approach for on-site and real-time detection, enabling immediate interventions and reducing the burden on healthcare systems. In this study, we present the development of a novel biosensor for point-of-care detection of infectious diseases. The biosensor utilizes innovative nanotechnology-based platforms coupled with specific biomolecular recognition elements to detect pathogen-specific markers. We discuss the design, fabrication, and optimization of the biosensor, along with its performance characteristics in terms of sensitivity, specificity, and detection limit. Furthermore, we evaluate the biosensor's feasibility for use in resource-limited settings and discuss its potential impact on improving global healthcare outcomes through early and accurate detection of infectious diseases.

Metabolomics, a comprehensive analysis of small molecules in biological systems, has emerged as a powerful tool in precision medicine for cancer. Mass spectrometry-based metabolomics has witnessed significant advancements in recent years, enabling the identification and quantification of metabolites with high sensitivity and accuracy. This review highlights the recent developments in mass spectrometry-based metabolomics and its applications in precision medicine for cancer. We discuss the analytical techniques, data processing methods, and statistical approaches utilized in metabolomics studies. Furthermore, we explore the role of metabolomics in cancer diagnosis, prognosis, treatment response prediction, and identification of novel therapeutic targets. We also address the challenges and future perspectives of mass spectrometry-based metabolomics in cancer research. Overall, the integration of metabolomics into precision medicine has the potential to revolutionize cancer management and improve patient outcomes.

Targeted drug delivery systems have emerged as promising approaches to enhance the therapeutic efficacy of drugs by selectively delivering them to the desired site of action while minimizing off-target effects. In this review, we discuss the current trends and future directions in targeted drug delivery systems. We explore various strategies employed to achieve targeted drug delivery, including nanocarriers, ligand-receptor interactions, stimuli-responsive systems, and cell-based delivery systems. We highlight the advantages and challenges associated with each approach and discuss their applications in different disease contexts, such as cancer, inflammatory diseases, and infectious diseases. Furthermore, we examine recent advancements in targeting strategies, including personalized targeting approaches and combination therapies. Finally, we discuss the future directions and potential impact of targeted drug delivery systems in improving therapeutic outcomes and patient care.

The human microbiome, comprising trillions of microorganisms residing in and on the human body, has emerged as a key determinant of human health and disease. In this review, we explore the role of the microbiome in human health and disease using a bioanalytical approach. We discuss the methodologies and techniques employed in microbiome analysis, including high-throughput sequencing, metagenomics, and metabolomics. We highlight the impact of the microbiome on various physiological processes, such as immune system modulation, nutrient metabolism, and drug metabolism. Furthermore, we explore the association between dysbiosis of the microbiome and various diseases, including inflammatory bowel disease, obesity, and autoimmune disorders. We also address the potential of modulating the microbiome as a therapeutic approach. By integrating bioanalytical approaches, we gain a deeper understanding of the complex interactions between the microbiome and human health, paving the way for targeted interventions and personalized medicine.